Jul 1st, 2022 - Generalized anxiety disorder (GAD) typically begins in early adulthood and persists throughout life. Many individuals with GAD report they have felt anxious their entire lives.

Jul 1st, 2022 - Mr. T, age 34, is a veteran who recently returned to civilian life.

Jul 1st, 2022 - A new Scandinavian study has confirmed previous data showing increased rates of cerebral venous thrombosis and thrombocytopenia after the AstraZeneca COVID-19 vaccine. The study also showed higher rates of several thromboembolic and thrombocytopenic outcomes after the Pfizer and Moderna mRNA vaccines, although these increases were less than the rates observed after the AstraZeneca vaccine, and ...

Jul 1st, 2022 - Is What You Call Probable…Impossible? Nearly 78% of physicians gave logically impossible answers when asked to estimate the probability of medical events happening, according to research. The mistake, called conjunction fallacy, can lead to serious clinical errors. Famous example: "Linda is 31 years old, single, outspoken, and very bright. She majored in philosophy. As a student, she was deeply...

Jun 30th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer-reviewed. Key Takeaways Korean acute coronary syndrome (ACS) patients who were started and remained on prasugrel after percutaneous coronary intervention (PCI) did not have rates of major adverse cardiac and cerebrovascular events (MACCE) any different than those started on another P2Y1...

Jun 30th, 2022 - The US Food and Drug Administration issued a warning today that the cancer drug duvelisib (Copiktra, Verastem Inc), a PI3 kinase inhibitor, may increase the risk of death and serious side effects. Duvelisib was approved in 2018 to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had received at least two prior therapies that did not work or stopped wo...

Jun 30th, 2022 - Six-year-old Grant Brown was not a strong swimmer. His mother told counselors that when she dropped him off on his first day at a North Carolina day camp. Carolynne Brown was assured the boy would be supervised. The lifeguard, a collegiate swimmer, never got that info, according to local reporting. On that day in July 2013, she was the only certified guard for 30-some campers plus adults — as m...

Jun 30th, 2022 - Physicians tend to excel in science and math, so it's a bit surprising that, in a new study, nearly 8 in 10 ― 78% ― committed a gaffe called the conjunction fallacy. Researchers asked doctors to estimate the probability of a sequence of events in a clinical scenario. But most gave answers that were logically impossible, the study found. In medicine, this type of mistake can lead to clinical mis...

Jun 30th, 2022 - LONDON — Weight loss, lipid reductions, and "robust improvements" in lipid species associated with nonalcoholic fatty liver disease were achieved in patients who were treated with pemvidutide in a first-in-human, phase 1 clinical trial reported at the annual International Liver Congress, sponsored by the European Association for the Study of the Liver. The presenting study investigator, Stephen...

Jun 30th, 2022 - LONDON — Resmetirom (Madrigal Pharmaceuticals) is a safe option for patients with nonalcoholic steatohepatitis (NASH), according to a pair of studies sharing results from the phase 3 MAESTRO NAFLD-1 trial. Not only was the investigational, oral, liver-directed, selective thyroid hormone-receptor beta-agonist well tolerated, its use led to reductions in liver fat, fibrosis, atherogenic lipids, a...

Jun 29th, 2022 - Key clinical point: Reduced doses of rituximab can be considered in patients with rheumatoid arthritis (RA) who have had treatment failure with multiple biologic disease-modifying antirheumatic drugs (bDMARD), significant comorbidities, and an initial sustained clinical response. Major finding: Over a 60-month follow-up, only 7.

Jun 29th, 2022 - Key clinical point: Obefazimod (ABX464 ) at a dose of 50 mg showed promising efficacy and was safe and well-tolerated in patients with moderate-to-severely active rheumatoid arthritis (RA). Major finding: A dose of 50 mg ABX464 vs.

Jun 29th, 2022 - Key clinical point: A higher proportion of patients with migraine treated with atogepant vs. placebo showed a significant reduction in the monthly migraine days (MMD) during the 12 weeks of treatment.

Jun 29th, 2022 - Key clinical point: Intravenous (IV) ketorolac plus metoclopramide failed to improve pain intensity in children presenting to the emergency department (ED) for the acute treatment of migraine compared with metoclopramide monotherapy. Major finding: The mean change in pain intensity as assessed by a 100 mm Visual Analog Scale at 120 minutes was −44 mm (95% CI 32-57 mm) in the monotherapy group a.

Jun 29th, 2022 - Key clinical point: Intradermal (ID) hepatitis B virus (HBV) vaccination with topical imiquimod pretreatment (ID-Imq) to the injection site was safe and provided superior seroprotection compared with intramuscular (IM) HBV vaccination with aqueous cream pretreatment (IM-Aq) in patients with inflammatory bowel disease (IBD). Major finding: Patients who received ID-Imq vs.

Jun 29th, 2022 - Key clinical point : Vedolizumab can be considered a safe and valid option for elderly patients with inflammatory bowel disease, with efficacy being unaffected by age in Crohn’s disease (CD), but slightly reduced in elderly vs. nonelderly patients with ulcerative colitis (UC).

Jun 29th, 2022 - Key Clinical Point: Maintenance therapy with subcutaneous risankizumab showed superior efficacy than withdrawal from risankizumab to receive subcutaneous placebo in patients with moderate-to-severe Crohn’s disease (CD). It also had a tolerable safety profile.

Jun 29th, 2022 - Key clinical point: Tofacitinib showed higher efficacy and comparable safety to vedolizumab in patients with ulcerative colitis (UC) with prior treatment failure with anti-tumor necrosis factor (anti-TNF) therapy. Major finding: Patients treated with tofacitinib vs.

Jun 29th, 2022 - Key Clinical Point: Intravenous risankizumab induction therapy is safe and effective in patients with moderate-to-severe Crohn’s disease (CD). Major finding: In the ADVANCE trial, Crohn’s Disease Activity Index clinical remission at week 12 was higher with 600 mg risankizumab (adjusted difference [Δ] 21% ) and 1200 mg ( Δ 17%) vs.

Jun 29th, 2022 - LONDON – Weight loss, lipid reductions, and “robust improvements” in lipid species associated with nonalcoholic fatty liver disease were achieved in patients who were treated with pemvidutide in a first-in-human, phase 1 clinical trial reported at the annual International Liver Congress, sponsored by the European Association for the Study of the Liver. The presenting study investigator, Stephen.